Viewing Study NCT02113800

Home

Certify Doc

Genes

Clinical Trials

CompTox

DrugMatrix

Open Targets

Products

Support

Bugs

Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug

Ignite Creation Date: 2025-12-26 @ 12:17 PM

Ignite Modification Date: 2026-01-01 @ 1:01 AM

Study NCT ID: NCT02113800

Status: COMPLETED

Last Update Posted: 2020-10-28

First Post: 2014-04-08

Is NOT Gene Therapy: True

Has Adverse Events: False

Brief Title: Safety and Tolerability of Everolimus as Second-line Treatment in Poorly Differentiated Neuroendocrine Carcinoma / Neuroendocrine Carcinoma G3 (WHO 2010) and Neuroendocrine Tumor G3 - an Investigator Initiated Phase II Study

Sponsor: AIO-Studien-gGmbH

Organization:

Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module References Module